Search
Cardiolipin Biosynthesis CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(11Z,14Z,17Z))
smpdb.ca/view/SMP0288078MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Duloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigationalDuloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine, (S)-duloxetineMebendazole
go.drugbank.com/drugs/DB00643ApprovedInvestigationalVet approvedA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]
Synonyms: (5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl esterMixtures: L-OMBRIX-DUET, L-OMBRIX-DUETDarifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalDarifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Synonyms: (S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-α,α-diphenyl-3-pyrrolidineacetamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsEmicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.
Products: HEMLİBRA 60 MG/ 0.4 ML S.C. ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, HEMLİBRA 150 MG/ 1 ML S.C. ENJEKSİYONLUK ÇÖZELTİ, 1 ADETDimenhydrinate
go.drugbank.com/drugs/DB00985ApprovedInvestigational[L32980,L32985,L32995] Dimenhydrinate is a combination of [Diphenhydramine] and [8-chlorotheophylline] in a salt form, with 53%-55.5% dried diphenhydramine, and 44%-47% died 8-chlorotheophylline. … [A33889] When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.
Synonyms: 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1), N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinateInternational brands: Vomex ABrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: BRIVIACT®10 MG, BRIVIACT® 10 MG/ML SOLUCIÓN ORALArgatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalArgatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. … Argatroban is a direct, selective thrombin inhibitor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: Argatra 1 mg/ml Infusionslösung, Argatroban Accord 1 mg/ml InfusionslösungSulfaquinoxaline
go.drugbank.com/drugs/DB11464ExperimentalVet approvedSulfaquinoxaline is a veterinary medicine which can be given to cattle and sheep to treat coccidiosis.It is available in Pakistan with Sanna Laboratories in combination with Amprolium and Vitamin K as
Products: SN ANTI-COCCI 45 mg/ml ORAL SOLUTION, COCCI 25%W/W PREMIX POWDEREvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … Evolocumab is a human IgG2 monoclonal antibody that targets the proprotein convertase subtilisin/kexin type 9 (PCSK9).
Products: REPATHA® 140 MG/ML, REPATHA 140 MG/ML SC ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADET